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“Duration of untreated psychosis:  
A proposition regarding treatment definition.” 
Rapport de synthèse 
La durée de psychose non traitée (Duration of Untreated Psychosis, DUP) est définie par le 
temps écoulé entre l’émergence d’un trouble psychotique et le début de son traitement. 
La réduction de la DUP est un des objectifs principaux des programmes spécialisés dans le 
traitement de la psychose émergente, de nombreux travaux de recherche suggérant qu’une 
DUP longue est associée à une évolution défavorable de la maladie. Ces résultats restent 
cependant controversés, certaines études ne démontrant pas une telle association. Cette 
contradiction dans les résultats pourrait être la conséquence d’un manque d’uniformité dans les 
définitions appliquées pour mesurer la DUP, plus particulièrement en ce qui concerne la 
définition de ce que l’on considère être « début » du traitement. En effet, si l’étude de la phase 
d’émergence de la pathologie psychotique a été le focus d’une attention considérable qui a 
conduit à un certain degré de consensus quant à sa définition, le concept de début du traitement 
n’est clairement pas défini de manière aussi homogène. Compte tenu de l’importance des 
enjeux relatifs à l’intervention précoce dans les troubles psychotiques, il nous a semblé utile 
d’explorer cette question de manière plus approfondie, considérant qu’un manque de consensus 
dans la définition de la DUP contribue certainement à troubler les résultats des études qui visent 
à évaluer son impact sur l’évolution de ces maladies.  En conséquence, l’objectif premier de ce 
travail est d’explorer l’impact de l’application de diverses définitions de début de traitement sur 
l’estimation de la DUP. 
 
Dans un premier article, publié dans Acta Neuropsychiatrica en 2009 (Duration of untreated 
psychosis : What are we talking about ?), le focus a été placé sur une revue de littérature 
concernant les définitions utilisées pour caractériser la fin de la DUP ainsi que sur les 
conséquences possibles d’un manque de précision dans cette définition sur l’évaluation de 
l’impact d’un retard de traitement dans la psychose débutante. Ce travail nous a permis 
d’identifier trois groupes principaux de définition de fin de DUP (End of DUP ; E-DUP) parmi les 
multiples critères utilisés dans les études publiées. E-DUP-1 est définie par la mise en route 
d’un traitement antipsychotique, le plus souvent sans tenir compte ni du dosage prescrit, ni de 
l’adhérence au traitement. E-DUP-2 est définie par l’entrée dans un programme de traitement 
spécialisé, et E-DUP-3 enfin est définie par la conjonction de la prescription d’un traitement 
antipsychotique adapté, de l’adhérence à ce traitement, et de la mise en route d’une prise en 
charge dans un programme spécialisé. En conclusion, nous relevions que cette grande variété 
dans les définitions appliquées pour l’évaluation de la DUP avait probablement contribué à 
l’aspect contradictoire des résultats des études de son impact sur l’évolution des psychoses et 
qu’il était donc temps de proposer une définition de consensus. 
 
La deuxième étude a été conduite dans le cadre d’un suivi de cohorte mis en place dans le 
programme de Traitement et Intervention Précoce dans les troubles Psychotiques (TIPP) établi 
dans le Département de Psychiatrie du CHUV à Lausanne depuis 2004. Les objectifs de cette 
seconde étude étaient au nombre de trois: (1) Exploration des variations de la DUP en fonction 
de l’application de trois principales définitions de fin de DUP (E-DUP) identifiées dans la 
littérature ; (2) Evaluation de la proportion de patients remplissant au moins une fois au cours 
des 18 mois de traitement la définition de E-DUP la plus compatible avec les directives de 
traitement proposées par l’International Early Psychosis Association (patient est à la fois engagé 
dans le traitement et se montre compliant à la médication, E-DUP-3); (3) Enfin, identification des 
facteurs qui caractérisent les patients qui ne remplissent jamais les critères de cette dernière 
définition. 
L’exploration de différentes durées de DUP en utilisant les trois définitions d’E-DUP a donné les 
résultats suivants : La DUP1 médiane (2.2 mois) était significativement plus courte que la DUP2 
(7.4 mois), et la DUP3 (13.6 mois) était significativement la plus longue des trois.  
De plus, 19.7% des patients n’avaient jamais rempli les critères de E-DUP-3 ; on peut donc 
considérer que près de 20% des patients traités dans ce programme spécialisé ne recevaient 
pas un traitement adéquat selon les directives intrernationales actuellement reconnues. Sur la 
base de ces chiffres, il apparaît clairement que, dans les études de l’impact de la DUP sur 
l’évolution de la psychose débutante, bon nombre des patients pour lesquels on considère que 
la DUP est terminée ne sont en fait pas adéquatement traités. Il est en conséquence très 
probable que ceci ait faussé les résultats de ces études, et qu’une définition plus restrictive 
permettrait de répondre de manière plus précise à cette question. 
Les patients qui ne remplissaient pas les critères E-DUP3 au cours des 18 premiers mois de 
traitement étaient caractérisés par un moins bon niveau de fonctionnement au cours de leur vie 
(« lower lifetime SOFAS » ;  p=0.017) et ils étaient plus susceptibles de consommer du cannabis 
à l’entrée du programme TIPP (χ2 (1, n=49)=4.241, p=0.039).   
Pour ceux qui avaient rempli les critères E-DUP-3 au cours des 18 mois, une longue DUP3 était 
associée avec un jeune âge au début des symptômes psychotiques (rs =-0.573, p<0.001), et 
avec un faible niveau de fonctionnement pré-morbide (score de PAS élevés (rs =0.373, 
p=0.001), niveau maximal au cours de la vie bas pour le GAF(rs =-0.367, p<0.001) et pour le 
SOFAS  (rs =-0.314, p=0.003)).  
 
En conclusion, ce travail a permis de mettre en évidence une grande variabilité dans la définition 
de la fin de la DUP parmi les études publiées jusque à ce jour, et l’impact important que le choix 
d’une ou l’autre de ces définitions peut avoir sur l’estimation de la DUP. De plus, nous avons 
observé que malgré la mise en place d’un programme spécialisé, près de 20% des patients ne 
remplissent pas les critères d’exposition à un traitement adéquat au cours des 18 premiers mois 
de prise en charge. Il est donc probable que l’estimation de l’impact de la DUP ait été faussé par 
cette variabilité, et il semble important que la communauté scientifique s’accorde sur une  
définition plus rigoureuse de cette variable. Enfin, certaines caractéristiques permettent 
d’identifier les patients qui sont à risque de ne pas remplir les critères de traitement adéquat a 
cours des 18 premiers mois de prise en charge ; il est possible qu’une identification précoce de 
ceux-ci permette la mise en place de stratégies mieux adaptées pour les aider à s’engager dans 
les soins. 
 
Le futur développement de ce travail sera d’évaluer l’impact de la DUP sur l’évolution des 
patients au cours des 36 mois de traitement proposés dans le programme TIPP, en appliquant 
les divers critères E-DUP, afin de voir si notre hypothèse que la variation des définitions a 
effectivement faussé les résultats de telles études. Nous devons pour cela attendre qu’un 
nombre suffisant de patients ait complété les 36 mois de traitement, de manière à avoir une 
puissance statistique suffisante pour répondre clairement à cette question.  
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Editorial
Duration of untreated psychosis: What are we
talking about?
Duration of untreated psychosis (DUP) broadly refers
to the time elapsing between onset of psychosis and
treatment initiation. Its relationship with outcome
has been intensely studied in the framework of
the development of early intervention strategies for
psychosis. Results of such research are however still
a matter of controversy, some studies showing a
negative impact of long DUP on outcome (1–4)
while others do not (5–8). In a systematic literature
review, Marshall (9) nevertheless concluded that
there is a significant, albeit small to moderate,
negative association between DUP and outcome, and
most early intervention programmes rank reduction
of DUP as a primary priority.
From a clinical point of view, reduction of DUP
emerges as a logical target when witnessing the col-
lateral damage suffered by patients who experience
long delays prior to onset of care (10). Addition-
ally, recent imaging data have shown that the pro-
drome and the early phase of psychotic disorders are
periods of active and progressive structural changes
in key brain areas such as the hippocampus (11).
If one assumes that there is an active process of
neuroprogression underlying these changes, then the
longer the DUP, the greater the time available for this
potentially neurotoxic process to unfold (12). The
nature of the pathogenic process remains to be fully
elucidated; however, it probably includes reduction
in neurotrophins, oxidative stress and inflamma-
tory cytokines. Given the evidence that appropri-
ate treatment is potentially neuroprotective (13),
reduction in DUP could therefore be associated with
reduction in potentially cumulative brain insult, and
hence improvement in symptomatic and functional
outcomes.
In the last few years, assessment of psychosis onset
has been the object of a considerable attention, and
this interest has led to both a degree of consensus
about its definition and the development of scales
specifically designed to determine the date of its
initial occurrence (14,15). A closer look at this lit-
erature reveals on the other hand that criteria applied
to define the endpoint of DUP, in other words the
time of treatment initiation, is much less consistent
and vary greatly between studies.
According to international guidelines, an adequate
treatment of first episode psychosis should combine
adapted medication (generally utilising low-dose
strategy) and psychosocial intervention delivered in
the context of easily accessible and specialised treat-
ment teams (16–18). However, despite the avail-
ability of such guidelines, the concept of ‘treatment
initiation’ usually refers to the commencement of
very incomplete and often ill-defined interventions
(Table 1). These include ‘initiation of medication’,
‘commencement of any form of treatment’, ‘initia-
tion of adequate treatment’, ‘time of first effective
treatment’, as well as ‘hospitalisation’ or ‘entry to
a specialised programme’. In addition, adherence to
treatment is in the vast majority of cases not assessed
when in fact clinical experience reveals that enroll-
ment in a specialised service or prescription of med-
ication does not necessarily equate with the person
being fully engaged with the service, receiving suf-
ficient psychosocial support, or taking medication as
prescribed.
In the studies mentioned above, it is therefore
highly likely that many patients for whom DUP
was defined as having concluded actually remained
untreated or partially treated. Only two studies
defined treatment initiation on the basis of adher-
ence to or observed response to medication treatment
(14,30). However, by focusing on this aspect of
treatment, they neglect the importance of psychoso-
cial intervention in the recovery process (31), while
recent randomised controlled trials have now clearly
proven that integrated early intervention programmes
that include specialised psychosocial treatment lead
first episode psychosis patients to a better outcome
than generic mental health programmes (32,33).
This lack of consistency in definition is concern-
ing, considering that an absence of consensus on
what ‘treatment initiation’ actually comprises could
very well be one of the critical factors that so far
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Table 1. Definitions of treatment initiation in the literature
Study Definition applied to initiation of treatment Limitations
Barnes et al. (19); Browne et al. (20); Craig et al. (5); Haas Initiation of medication • Absence of assessment of adherence to treatment
et al. (21); Ho and Andreasen, (7); Szymanski et al. (22); • Does not take into account psychological and case
Tirupati et al. (23). management intervention
Wiersma et al. (24) Any form of treatment • Absence of definition of treatment
Larsen et al. (25) Initiation of adequate treatment • Absence of definition of response
Addington et al. (26) First effective treatment • No definition of effective treatment
• Problem with treatment resistance
Hafner et al. (27); Kalla et al. (28) Hospitalisation • Selection bias towards patients with more acute
symptoms
Carbone et al. (29); Schimmelmann et al. (4) Entry to specialised programme • Does not mean patients are adherent to treatment
Malla et al. (30) Medication for at least 2 months or significant
response
• Treatment definition restricted to medication
Singh et al. (14) Medication with adherence (at least 75% of the
dose for 75% of the time)
• Treatment definition restricted to medication
limited the conclusiveness of studies exploring poten-
tial consequences of DUP. While research exploring
DUP impact on outcome should not interfere with
common sense arguments justifying the necessity
of mental health services reforms aimed at facili-
tating treatment access for patients with psychosis
(10), conclusive research on DUP, based on valid
data, would only provide more momentum to such a
reform process.
It seems therefore timely to establish a clearer
definition of what should be considered as the end
of the DUP period. First, given that medication is a
key element in treatment of the vast majority of first
episode psychosis patients, antipsychotic treatment
initiation should belong to the definition. However,
adherence to treatment ought to be assessed as well
and the medication criterion considered fulfilled only
if patients have taken their treatment for at least
75% of the time during at least 4 weeks. Second,
based on the above data supporting the efficacy
of specialised treatment, end of DUP should be
considered only when patients are well engaged
in an early intervention programme. It is clear
that psychosocial treatments remain inconsistently
available, and subject to the vagaries of service,
economic, training and resource variables, but this
is precisely what research on the impact of DUP is
all about: to show that adequate treatment provided
early has a positive impact on outcome of psychosis.
Once this point established, the argument to justify
the need for a reform of mental health programmes
and for an earlier access to adequate psychosocial and
medication treatment in early psychosis would only
be stronger. However, in order to supply evidence-
based arguments to this debate, the definition of DUP
needs to be applied with more precision.
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Abstract 
Aim: Duration of untreated psychosis (DUP) refers to the time elapsing between 
psychosis onset and treatment initiation. Despite a certain degree of consensus 
regarding the definition of psychosis onset, the definition of treatment 
commencement varies greatly between studies and DUP may be underestimated 
due to lack of agreement. In the present study three sets of criteria to define the end 
of the untreated period were applied in a first-episode psychosis cohort to assess the 
impact of the choice of definition on DUP estimation.  
Method: The DUP of 117 patients admitted in the Treatment and early Intervention in 
Psychosis Program Psychosis (TIPP) in Lausanne was measured using the following 
sets of criteria to define treatment onset; 1- initiation of antipsychotic medication, 2- 
entry into a specialised program and 3- entry into a specialised program and 
adequate medication with a good compliance.  
Results: DUP varied greatly according to definitions, the most restrictive criteria 
leading to the longest DUP (Median DUP1=2.2, DUP2=7.4, DUP3=13.6 months). 
19.7% of the patients who did not meet these restrictive criteria had poorer pre-
morbid functioning and were more likely to use cannabis. Longer DUP3 was 
associated with poorer pre-morbid functioning and with younger age at onset of 
psychosis. 
Conclusions: These results underline the need for a unique and standardised 
definition of the end of DUP. We suggest that the most restrictive definition of 
treatment should be employed when using the DUP concept in future research. 
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Introduction 
Duration of untreated psychosis (DUP) broadly refers to the time elapsing between 
psychosis onset and treatment initiation, with its reduction being one of the main 
targets of early intervention strategies.1 Despite a systematic review showing a 
significant, negative association between DUP and outcome,2 results of such 
research are still a matter of controversy; some studies have shown a negative 
impact of long DUP on outcome,3-6 while others have not.7-10 These contradicting 
results may be linked to the wide variety of definitions of DUP.  
The assessment of psychosis onset has been the object of considerable attention, 
resulting in a certain degree of consensus regarding its definition and the 
development of scales specifically designed to determine the date of its occurrence.11 
12 However, this is not true for criteria applied to define the end of the DUP (E-DUP) 
period.  Despite the availability of clear guidelines for the treatment of early 
psychosis,13-15 the definition of treatment has varied greatly between studies. 
Definitions include: “initiation of medication”,7 9 16-20 “start of any form of treatment”,21 
“initiation of adequate treatment”,22 “time of first effective treatment”,23 
“hospitalization”24 25 and “entry to a specialized program”.26 Most of these definitions 
are likely to underestimate DUP;27 entry to a program or prescription of medication 
does not mean that patients are sufficiently engaged to actually receive either 
satisfactory psychosocial support or adequate exposure to medication. 
Consequently, for many studies, DUP may be considered over when patients were 
actually far from receiving adequate treatment.10 13 As a result, there is little 
generalisability across studies and investigations on DUP’s predictive validity may be 
of limited value.  
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In this study, we examined the clinical utility of various DUP definitions in first-
episode psychosis (FEP) patients admitted in a specialised early intervention 
program. Three sets of criteria to define the E-DUP were studied. The first definition 
(E-DUP1) is based on the criterion most commonly used in the determination of DUP, 
which is initiation of the first antipsychotic treatment7 9 16-20 regardless of its dosage 
and patients’ adherence. The criterion defining E-DUP2, i.e. entering a specialised 
FEP program, is based on data suggesting that FEP patients receiving treatment in 
specialised programs have a better outcome28 29 and lower disengagement rates29-31 
compared to patients treated in standard mental health facilities. E-DUP3 is the most 
restrictive, with patients being included in the specialised program, treated with 
antipsychotics and compliant to this treatment. This definition is in line with 
international guidelines to define adequate treatment for FEP patients, i.e. patients 
should be exposed to adapted psychosocial and pharmacological treatment.13-15  
The aims of the study were: (1) To explore differences in DUP deriving from the three 
definitions of E-DUP; (2) To assess the prevalence of patients who do not reach 
restrictive criteria (E-DUP3); (3) To identify predictors of persistent failure to meet E-
DUP3 criteria, as well as predictors of prolonged DUP according to E-DUP3 
definition. 
Methods 
Participants and Setting 
Since April 2004 a specialised program for early intervention in psychotic disorders, 
the Treatment and early Intervention in Psychosis Program (TIPP32 33), has been 
implemented in the Department of Psychiatry of the Lausanne University Hospital in 
Switzerland. Inclusion criteria are: age between 18 and 35, reside in the catchment 
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area (Lausanne and surroundings; population: about 250 000) and have met 
threshold criteria for psychosis, as defined by the “Psychosis threshold” subscale of 
the Comprehensive Assessment of At Risk Mental States scale (CAARMS12). 
Exclusion criteria are: more than a total of 6 months of anti-psychotic medication, 
psychosis related to intoxication or organic brain disease, IQ below 70.  
The program is aimed at facilitating FEP patients’ access and engagement in 
treatment.30 34 It comprises an outpatient clinic with case management, a specialised 
inpatient unit and a community treatment team.35-37 Treatment is conducted on the 
basis of the International Early Psychosis Clinical Guidelines.14 Patients are seen by 
case managers at least twice a week after discharge from any hospital admission, 
and once a week in the early phase of treatment (first 12 weeks). Retention of 
patients has been very high, with a rate of about 85%.30 Approval has been granted 
by local ethics committee to access the TIPP database for research purposes. All 
patients who had been enrolled in the program for at least 18 months by March 2009 
were considered for the present study. 
Assessments 
A specially designed questionnaire is routinely filled on the basis of information 
gathered from patients and their family after entry into TIPP. The questionnaire 
addresses demography, symptoms and functioning. Patients are also assessed 
prospectively (at months 2, 6, 12, 18, 24 and 36 by psychologist and case managers) 
in order to monitor symptomatic and functional evolution, as well as adherence to 
treatment and evolution of co-morbidities.   
Premorbid characteristics: Premorbid functioning was assessed with the Global 
Assessment of Functioning Scale (GAF38), social and vocational functioning with the 
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Social and Occupational Functioning Assessment Scale (SOFAS38), and social 
adjustment with the Premorbid Adjustment Scale (PAS39). Familial socio-economical 
status was assessed according to parents’ profession, as proposed by Chandola40 
and classified as: 1- high, 2- intermediate and 3- low. Migration was defined as being 
born outside of Switzerland. The severity of illness prior to admission to the clinical 
program was assessed using the Clinical Global Impressions-Severity of Illness scale 
(CGI-S41).  
Characteristics at entry in the program: Level of functioning was assessed with the 
GAF and social and vocational functioning with the SOFAS. Substance use disorders 
(SUD) was evaluated according to the DSM-IV-TR42 and with the Case Manager 
Rating Scale (CMRS43). Patients were also assessed regarding their insight into 
illness on a three point scale: 0- no insight (denying any behavioural change and any 
need for treatment); 1- partial insight (admits behavioural change but denies illness or 
need for treatment); 2- good insight (admits illness and agrees with need for 
treatment). 
Outcome and clinical characteristics: Adherence to medication was assessed by 
case managers at each follow-up time line, based on interviews with patient and 
family. Ratings were defined as follows according to Keck and collaborators44: 1- Full 
adherence (taking medication as prescribed at least 75% of the time); 2- partial 
adherence (from 25% to 75% of the time); 3- non-adherence to medication (less than 
25% compliance). Clinical diagnosis was based on DSM-IV criteria, using the Mini-
International Neuropsychiatric Interview (M.I.N.I.45). Among co-morbid diagnoses, 
SUD, and more specifically Tetra-Hydro-Cannabinol (THC) use, were recorded 
separately from other co-morbidities, in order to allow separate analyses. 
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Measurement and definitions of DUP 
Psychosis onset was defined using the Nottingham Onset Schedule11 and the 
CAARMS exit criteria. TIPP’s clinicians are trained to determine the date of onset of 
sustained positive psychotic symptoms on the basis of interview with patients and 
relatives.  Where appropriate, this date can be modified over the course of treatment 
if new information allowing a more precise identification of this date is gathered, as 
patients become clinically more stable and more capable to reflect on symptom 
onset. A final decision regarding DUP was made on the basis of all available 
prospective data contained in the clinical file 18 months after entry in the program. To 
minimize the chance of diagnostic instability known to occur in patients presenting a 
first episode of psychosis46, another evaluation of the diagnosis was done for patients 
who reached the 36-month benchmark.  
E-DUP has been delineated on the basis of three situations frequently encountered 
in clinical and research settings: E-DUP1 was defined as the time of initiation of 
antipsychotic treatment, regardless of dosage and compliance; E-DUP2 was defined 
as the date of entry into TIPP; E-DUP3 was defined as being included in the TIPP, 
receiving adequate medication according to international guidelines13-15 and taking 
medication at least 75% of the time for 4 weeks.44 Three DUP values were obtained 
for each patient by calculating the time elapsed between psychosis onset and the 
dates when the various E-DUP criteria were met. 
Data analyses 
Skewness and kurtosis statistics were used to determine whether the data conformed 
to a normal Gaussian distribution47. Data normally distributed were presented 
descriptively in the form of means (M) and standard deviations (SD). Otherwise, 
  
8 
descriptive statistics included the median ± 1st and 3rd quartiles. DUP values were not 
normally distributed and the effect of definition was assessed using the Friedman’s 
Two Way ANOVA by Ranks. This was followed by multiple pairwise comparisons 
using the Wilcoxon’s signed rank test with Bonferroni correction applied to alpha 
(α/3=0.05/3 =0.02).  
Two groups were derived based on whether the patient met the restrictive criteria (E-
DUP3) or not. To determine differences between these two groups on premorbid, 
demographic, clinical and functional variables, the Mann-Witney test was used when 
the dependent variable was continuous and the chi-squared test (χ2) when the 
dependent variables was categorical. For significant χ2 (p< 0.05), there was 
examination of standardized residuals (z) to determine which cells contributed to the 
different chi-square value48, only the p-values associated with the z-statistic are 
reported in the text. 
Spearman’s rho (rs) correlation coefficient was used to examine the relationships 
between premorbid variables and length of DUP.  
Analyses were performed using the Statistical Package for Social Sciences Version 
15 (SPSS 15.0; Chicago, IL.). 
Results 
Patients’ characteristics 
A total of 156 patients had been in treatment for at least 18 months as of March 
2009. Of these, three did not meet study criteria (diagnosis other then psychosis) and 
data was incomplete for 36 subjects. A total of 117 patients were included in the 
study.  
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Table 1 shows patient’s demographic, premorbid and pre-admission to the TIPP 
attributes. Patients were predominantly males, displayed high socio-economic status 
and half of them had a history of migration. PAS score suggests that patients 
displayed a low premorbid level of functioning compared to the general population 
where a score lower than 0.2 is typically found.39 At the time of their life when the 
severity of symptoms was at its worst, patients presented a high severity of illness 
reflected by a high CGI score, and low GAF and SOFAS scores. 
Table 2 shows clinical and functional profiles at entry in the program. In line with 
other FEP cohorts,49 many patients displayed a lack of insight. The majority of 
patients were suffering from schizophrenia and almost half of patients presented a 
SUD, typically cannabis. Some patients were diagnosed with one or more non-SUD 
co-morbidities: major depressive episode without psychotic symptoms (16.2%), 
personality disorder (9.4%), PTSD (4.3%), eating disorder (2.6%), dissociative 
disorder (1.7%), OCD (1.7%), anxiety disorder (0.85%) and social phobia (0.85%).  
Duration of Untreated Psychosis 
Figure 1 displays DUP values according to the three E-DUP definitions; differences 
between median DUP1, DUP2 and DUP3 were statistically significant (Friedman’s χ2 
(2, n=94)=113.04, p<0.001).  Median DUP1 (2.2 months) was significantly lower than 
DUP2 (7.4 months), and DUP3 (13.6 months) was significantly the longest among all 
three DUPs (DUP1-DUP2 (z=-5.608, p<0.002); DUP1-DUP3 (z=-7.904, p<0.020); 
DUP2-DUP3 (z=-5.409, p<0.020)).  
Only 19.7% of the patients failed to fulfil the most restrictive definition of treatment (E-
DUP3). Patients who did not meet DUP3 criteria had worse lifetime-SOFAS 
(p=0.017) and were more likely to use THC at entry in the program (χ2 (1, 
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n=49)=4.241, p=0.039) when compared to those who did meet DUP3 criteria. No 
difference on demographic, and other pre-morbid or baseline characteristics were 
found. 
Longer DUP3 was associated with younger age at psychosis onset (rs =-0.573, 
p<0.001), higher PAS scores (rs =0.373, p=0.001), lower best-lifetime GAF scores (rs 
=-0.367, p<0.001) and lower best-lifetime SOFAS scores (rs =-0.314, p=0.003). 
Discussion  
DUP is a widely used concept and its reduction is the focus of many early 
intervention programs. However, despite its importance, there is wide variability in 
how treatment onset is defined. The lack of consensus regarding E-DUP’s definition 
limits its value in both clinical and research settings. This study compares three 
commonly used definitional models of DUP and shows how different the measured 
duration is from a definition to another. These results clearly show the importance of 
defining a unique and standardised definition of the end of DUP.  
As expected, DUP varied strongly depending on how restrictively treatment initiation 
was defined. Consequently, failure to standardise the definition of DUP when 
exploring its impact on treatment characteristics and outcome in FEP, is likely to have 
contributed to a lack of generalisability across studies and inconsistencies in 
research findings. Unfortunately, review papers and meta-analysis in this domain 
have failed to take this element into account, and have therefore neglected a 
potentially significant confounding factor. As a consequence, in order to really clarify 
the issue of the potential impact of DUP on outcome in FEP, it is timely to propose a 
consensual definition for the end of the DUP period. 
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E-DUP1, defined by the initiation of the first antipsychotic treatment regardless of its 
dosage and patients’ adherence was relatively brief in our sample (median of 2.2 
months), reflecting a rapid diagnosis and access to pharmacological treatment. 
Indeed, due to global high standard of living and universal health insurance system, 
access to primary medical care is easy in the Lausanne region. However, reaching E-
DUP1 criterion does neither mean that patients will be engaged in a therapeutic 
process, nor that they will continue to be compliant with the prescribed medication. In 
a previous study conducted in Lausanne before the implementation of a specialised 
early psychosis program50, following a first hospitalisation, 48% of patients suffering 
from a FEP did not attend their first appointment in the outpatient clinic. Another 
recent study showed that FEP patients prescribed with antipsychotics are not 
necessarily compliant33. These observation underline the fact that a first contact with 
psychiatric services and the prescription of a pharmacological treatment is no 
guarantee for appropriate health services engagement and exposure to adequate 
treatment.  
Patients with FEP who are treated in specialised first episode program have better 
outcomes28 29 and lower rates of disengagement29-31 compared to FEP patients 
treated in standard mental health facilities. Criterion defining E-DUP2, i.e. entering a 
specialised FEP program, is therefore relevant. The observation that DUP2 was more 
than 3 times longer than DUP1 is therefore concerning (median DUP2 = 7.37 
months) and suggests that access to our program needs to be improved. This 
improvement could be achieved through awareness campaigns and strengthening of 
connections with primary care facilities.  
  
12 
De Haan51 has suggested that delay in intensive psychosocial treatment may be a 
more important predictor of negative symptoms at outcome than is delay in 
introduction of antipsychotic alone. Similarly, current clinical guidelines for FEP 
treatment suggest that patients should be exposed to adapted psychosocial and 
pharmacological treatment.10 13 In the present study, E-DUP3 definition criteria, which 
correspond to both engagement into a specialised program and FEP clinical 
guidelines regarding medication,13-15 were reached only after a median of 13.63 
months. DUP3 was almost six times longer than the time elapsing between psychosis 
onset and first prescription of antipsychotic medication (DUP1). This illustrates once 
again that early intervention in psychotic disorders goes beyond earlier diagnosis and 
medication prescription. Early intervention needs to include psycho-education and 
promotion of engagement of the patients.  
The proportion of patients who failed to reach E-DUP3 criteria was 19.7%. This rate 
is in keeping with data stemming from a retrospective file audit study49 conducted at 
the Early Psychosis Prevention and Intervention Centre (EPPIC, Melbourne, 
Australia), where 18.8% of patients were persistent medication refusers, defined as 
never taking antipsychotic for more than 3 consecutive weeks, over an 18-month 
treatment period.33 Non-adherence to treatment and medication is a challenging 
issue for early intervention programs given that it is related to poorer outcome.33  
Patient’s characteristics that predicted failure to meet E-DUP3 criteria over the 
treatment period were examined. Early identification of these predictors may allow 
the implementation of specific strategies to promote treatment adherence. In line with 
previous findings,33 52 a lower premorbid SOFAS was associated with failure to meet 
E-DUP3 criteria over the treatment period. Furthermore, cannabis use at entry to the 
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TIPP was also associated with the same outcome, underlying the importance of 
tailored intervention aimed at reducing substance abuse in FEP. Interestingly, poor 
insight and high CGI scores at entry were not correlated to later failure to meet E-
DUP3 criteria, suggesting that severe clinical manifestations and absence of insight 
at baseline should not lead to undue pessimism regarding capacity of patients to later 
engage in treatment.  
The present study also aimed at identifying which characteristics were associated 
with a longer DUP when treatment was defined by restrictive criteria (E-DUP3). In 
line with other studies,6 53 54 younger age at onset of psychosis and poorer premorbid 
level of functioning (higher PAS score, low scores of best-lifetime SOFAS and GAF) 
were associated with longer DUP3. However, contrary to findings from Peralta55, no 
correlation between lower socio-economic status and DUP3 was found. This may be 
due to differences between samples and the small number of patients with low socio-
economic status in the sample used in the present study. 
A few limitations should be considered when interpreting these results. First, even if a 
consensus exists regarding the definition and the tools that can be applied to define 
psychosis onset11 12, a precise dating of this event remains subject to a potentially 
great amount of imprecision. However, a particular effort was made to update 
relevant data throughout the treatment period whenever new information allowed a 
more precise estimation of this date. Secondly, the sample size was rather small, and 
results may not be generalised to FEP patients treated in other socio-economic 
context. However, despite these limitations, the fact that all consecutive patients 
treated in the program were entered in the study provides a sample that is likely to be 
highly representative of FEP patients treated in the Lausanne area. 
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In conclusion, the present results clearly show that the absence of a consensus for 
the definition of the end of DUP can lead to major differences in the determination of 
time elapsing between psychosis onset and treatment initiation. Thus, there is an 
urgent need to harmonise criteria applied in studies exploring the impact of DUP on 
outcome in FEP. DUP has been put forward as a key target for early intervention. 
However, the controversy about its validity as an outcome predictor has become on 
focus of criticism for those who question the relevance of early intervention 
strategies. If one is to assess the impact of DUP in psychotic disorders, definition of 
treatment needs to correspond to what expert consensus have defined as adequate 
treatment of a FEP. This is likely to shed light on the unfortunately high proportion of 
patients who do not receive adequate treatment despite the implementation of 
specialised programs. In turn, in addition to allow a better evaluation of the impact of 
treatment delay in psychotic disorders, it could inspire both clinicians and researchers 
to develop new strategies to help patients to adhere to treatment. Therefore, we 
propose to use the restrictive definition of the end of DUP that corresponds to these 
criteria in any clinical or research setting interested in using this measurement. 
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